$250M ATM Offering Could Dilute Kala Bio Shareholders by Over 1,800%
KALA is trading near its 52-week low of $0.701 (2.7% above the low).
Summary
Kala Bio filed for an at-the-market offering of up to $250 million in common stock, a massive capital raise relative to its $13.7 million market cap. The offering follows a 1-for-50 reverse split in May and a $350 million shelf registration, signaling urgent cash needs. With the stock trading near its 52-week low of $0.70, the potential dilution is extreme—over 1,800% at current prices. This comes after a former major investor sold down below 5% and amid ongoing going concern doubts. The company is burning cash and needs funding to continue operations.
At the time of this announcement, KALA was trading at $0.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.7M. The 52-week trading range was $0.70 to $1,030.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.